Michael Randall, MD
ACGME FELLOW
Medicine
School of Medicine

Education & Training

Show all (3) Hide

• Internal Medicine Residency Johns Hopkins Hospital 06/2022
• MD University of Pennsylvania 05/2019
• BA Dartmouth College 06/2012

Publications (12)

Top publication keywords:
Myelodysplastic SyndromesCyclophosphamideUbiquitin-Protein LigasesBone Marrow TransplantationTransplantation ConditioningHematopoietic Stem Cell TransplantationBRCA1 ProteinHaploinsufficiencyNeuroblastomaWnt3A ProteinAxin ProteinAdenosine Diphosphate RiboseGlypicansTumor Suppressor ProteinsCD56 Antigen

• Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide.
  Bone marrow transplantation 2024 Sinanidis I, Hochman MJ, Tsai HL, Randall MP, Bonilla B, Varadhan R, Ambinder AJ, Jones RJ, DeZern AE, Karantanos T
• BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.
  Journal of the National Cancer Institute 2024 Randall MP, Egolf LE, Vaksman Z, Samanta M, Tsang M, Groff D, Evans JP, Rokita JL, Layeghifard M, Shlien A, Maris JM, Diskin SJ, Bosse KR
• Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.
  Journal of the National Cancer Institute 2024 Kim J, Vaksman Z, Egolf LE, Kaufman R, Evans JP, Conkrite KL, Danesh A, Lopez G, Randall MP, Dent MH, Farra LM, Menghani NL, Dymek M, Desai H, Hausler R, Hicks B, Auvil JG, Gerhard DS, Hakonarson H, …
• Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.
  Cancers 2023 Randall MP, Spinner MA
• The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances.
  Cancer journal (Sudbury, Mass.) 2023 Randall MP, DeZern AE

Show all (7 more) Hide

• Tafasitamab at the blood-brain barrier.
  British journal of haematology 2023 Rauschecker AM, Mo SS, Randall M, Shen-Sampas J, Rubenstein JL
• Genetic susceptibility to neuroblastoma: current knowledge and future directions.
  Cell and tissue research 2018 Ritenour LE, Randall MP, Bosse KR, Diskin SJ
• Axin phosphorylation in both Wnt-off and Wnt-on states requires the tumor suppressor APC.
  PLoS genetics 2018 Tacchelly-Benites O, Wang Z, Yang E, Benchabane H, Tian A, Randall MP, Ahmed Y
• A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
  Journal of gastrointestinal oncology 2018 Windon AL, Loaiza-Bonilla A, Jensen CE, Randall M, Morrissette JJD, Shroff SG
• Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.
  Cancer cell 2017 Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi KS, Kendsersky NM, Randall M, Donovan L, Morrissy S, Sussman RT, Zhelev DV, Feng Y, Wang Y, Hwang J, Lopez G, Harenza JL, Wei JS, …
• Wnt pathway activation by ADP-ribosylation.
  Nature communications 2016 Yang E, Tacchelly-Benites O, Wang Z, Randall MP, Tian A, Benchabane H, Freemantle S, Pikielny C, Tolwinski NS, Lee E, Ahmed Y
• Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.
  mAbs 2016 Feng Y, Wang Y, Zhu Z, Li W, Sussman RT, Randall M, Bosse KR, Maris JM, Dimitrov DS